FDA approves BridgeBio's Attruby (acoramidis) for ATTR-CM to reduce CV death and hospitalization

BridgeBio Pharma, Inc.

Attruby is first and only approved TTR stabilizer with label specifying near-complete stabilization (≥90%).
Phase 3 ATTRibute-CM: 42% reduction in composite ACM and recurrent CVH at Month 30; 50% reduction in cumulative CVH events.
BridgeBio to receive $500M payment under royalty funding agreement upon approval.
List price: $18,759.12 for 28-day supply; free for life for U.S. trial participants.
MAA submitted to EMA; decision expected in 2025; Bayer has exclusive EU commercialization rights.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.